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Background: To externally validate a risk prediction algorithm (QCovid) to estimate mortality 
outcomes from COVID-19 in adults in England.   
 
Methods:  Population-based cohort study using the ONS Public Health Linked Data Asset, a cohort 
based on the 2011 Census linked to Hospital Episode Statistics, the General Practice Extraction Service 
Data for pandemic planning and research, radiotherapy and systemic chemotherapy records. The 
primary outcome was time to COVID-19 death, defined as confirmed or suspected COVID-19 death as 
per death certification. Two time periods were used: (a) 24th January to 30th April 2020; and (b) 1st May 
to 28th July 2020. We evaluated the performance of the QCovid algorithms using measures of 
discrimination and calibration for each validation time period. 
 
Findings:  The study comprises 34,897,648 adults aged 19-100 years resident in England. There 
were 26,985 COVID-19 deaths during the first time-period and 13,177 during the second.  The 
algorithms had good calibration in the validation cohort in both time periods with close correspondence 
of observed and predicted risks. They explained 77.1% (95% CI: 76.9% to 77.4%) of the variation in 
time to death in men in the first time-period (R2); the D statistic was 3.76 (95% CI: 3.73 to 3.79); 
Harrell’s C was 0.935 (0.933 to 0.937). Similar results were obtained for women, and in the second 
time-period. In the top 5% of patients with the highest predicted risks of death, the sensitivity for 
identifying deaths in the first time period was 65.9% for men and 71.7% for women.  People in the top 
20% of predicted risks of death accounted for 90.8% of all COVID-19 deaths for men and 93.0% for 
women. 
 
Interpretation: The QCovid population-based risk algorithm performed well, showing very high levels 
of discrimination for COVID-19 deaths in men and women for both time periods. It has the potential to 
be dynamically updated as the pandemic evolves and therefore, has potential use in guiding national 
policy. 
 
Funding: National Institute of Health Research 
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RESEARCH IN CONTEXT 
 
Evidence before this study 
  
Public policy measures and clinical risk assessment relevant to COVID-19 need to be aided by 
rigorously developed and validated risk prediction models. A recent living systematic review of 
published risk prediction models for COVID-19 found most models are subject to a high risk of bias 
with optimistic reported performance, raising concern that these models may be unreliable when applied 
in practice.  A population-based risk prediction model, QCovid risk prediction algorithm, has recently 
been developed to identify adults at high risk of serious COVID-19 outcomes, which overcome many 
of the limitations of previous tools. 
  
Added value of this study 
  
Commissioned by the Chief Medical Officer for England, we validated the novel clinical risk 
prediction model (QCovid) to identify risks of short-term severe outcomes due to COVID-19. We 
used national linked datasets from general practice, death registry and hospital episode data for a 
population-representative sample of over 34 million adults. The risk models have excellent 
discrimination in men and women (Harrell’s C statistic>0.9) and are well calibrated. QCovid represents 
a new, evidence-based opportunity for population risk-stratification.  
 
 
Implications of all the available evidence 
 
QCovid has the potential to support public health policy, from enabling shared decision making 
between clinicians and patients in relation to health and work risks, to targeted recruitment for clinical 
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INTRODUCTION   
   
The first cases of SARS-CoV-2 infection were reported in the United Kingdom (UK) on the 
24th January 2020, with the first COVID-19 death on the 28th February 2020. As of 19 January 2021, 
there have been over 90,000 deaths from COVID-19 in the UK, and over 2 million deaths globally1.   
Emerging evidence throughout the course of the pandemic, initially from case series, and then 
cohorts of individuals with confirmed SARS-CoV-2 infection, has demonstrated associations of age, 
sex, certain co-morbidities, ethnicity and obesity with adverse COVID-19 outcomes such as 
hospitalisation and death2-9. There is now a growing knowledge base regarding risk factors for severe 
COVID-19. As many countries are re-introducing ‘lockdown’ measures and vaccination programmes 
have started being rolled out, there is an opportunity to develop more nuanced guidance10 based on 
predictive algorithms to inform risk management decisions.  Better knowledge of individuals’ risks 
could also help guide decisions on managing occupational risk and in targeting of vaccines to those 
most at risk. Whilst several risk prediction models have been developed, a recent systematic review 
found that they all have high risk of bias and that their reported performance is optimistic11.   
The use of primary care datasets such as QResearch with linkage to registries such as death 
records and hospital admissions data represents an innovative approach to clinical risk prediction 
modelling for COVID-19 which has successfully been developed, validated, and implemented in the 
NHS over the last 10 years12-14. It provides accurately coded, individual-level data for very large 
numbers of people representative of the national population. This approach was used to develop the 
QCovid prediction models15 drawing on the rich phenotyping of individuals with demographic, medical 
and pharmacological predictors to allow robust statistical modelling and evaluation. Such linked 
datasets have a track record for the development, and evaluation of established clinical risk models 
including for cardiovascular disease12, diabetes14 and mortality13. Whilst QCovid predicts both COVID-
19 hospital related admission and COVID-19 death, the aim of this analysis is to validate the mortality 
outcome which estimate the risks of becoming infected and subsequent death due to COVID-19 in an 
extremely large national cohort.  A companion study currently underway will externally validate these, 




METHODS   
   
The Chief Medical Officer for England asked the New and Emerging Respiratory Virus Threats 
Advisory Group (NERVTAG), to develop and validate a clinical risk prediction model for COVID-19 
in line with the emerging evidence. The resulting QCovid  model was developed and validated using 
the QResearch database and reported in accordance with TRIPOD19 and RECORD20 guidelines and 
with input from a patient advisory group. The original protocol is published 21 along with the results of 
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the paper reporting the original derivation and validation of the model15. This paper reports the 
validation of the model on an independent data source. 
  
  
Study design and data sources   
We undertook a validation cohort study of individuals aged 19-100 years using the Office for 
National Statistics (ONS) Public Health Linked Data Asset.  This dataset is based on the 2011 Census 
in England, linked at individual level using the NHS number to mortality records, Hospital Episode 
Statistics and the General Practice Extraction Service (GPES) Data for pandemic planning and research. 
To obtain NHS numbers, the 2011 Census was linked to the 2011-2013 NHS Patient Registers using 
deterministic and probabilistic matching, with an overall linkage rate of 94.6%. We excluded patients 
(approximately 13.1%) who did not have a valid NHS number. For the purpose of the validation of the 
QCovid algorithm, we further linked radiotherapy and systemic chemotherapy records based on NHS 
number. The ONS Public Health Linked Data Asset includes data on most patients used to develop the 
QCovid algorithm, but also includes patients registered with practices using IT systems other than 
EMIS, such as TPP (used by 35% of GP practices). 
We identified a cohort of all individuals aged 19-100 years who were enumerated at the 2011 
Census and registered alive and resident in England on 24th January 2020.  Patients entered the cohort 
on 24th January 2020 (date of first confirmed COVID-19 case in UK) and were followed up until they 
had the outcome of interest or 28th July 2020, which is the date up to which linked data were available 
at the time of the analysis. This also extends the period of observation beyond the original QCovid 
study. We divided the study period into two time periods: 24th January 2020 to 30th April 2020 and 01 
May 2020 to 28th July 2020. 
   
Outcomes    
The outcome was time to COVID-19 death (either in hospital or out of hospital), defined as 
confirmed or suspected COVID-19 death as identified by two ICD10 codes (U07.1 or U07.2) recorded 
on the death certification.   
 
Predictor variables    
We derived pre-existing conditions and demographic characteristics using the same definitions 
as used to develop the QCovid algorithm. The primary care records used in the ONS Public Health 
Linked Data Asset were based on an existing GPES dataset which included many but not all of the 
relevant clinical codes used to develop the QCovid algorithm.  Nonetheless, we derived most of the pre-
existing conditions, although we could not identify patients who had a solid organ or bone marrow 
transplant in the past six months; those on kidney dialysis; those with sickle cell disease or severe 
combined immune deficiency syndrome; Similarly, we could not distinguish between patients suffering 
from type 1 or type 2 diabetes. Variables used to validate the QCovid algorithm are listed in Box 1.     
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Model validation   
We fitted an imputation model to replace missing values for body mass index (BMI), using 
predicted values from linear regression models stratified by sex. Predictors included all predictor 
variables in the QCovid algorithm, interacted with age.    
We applied the QCovid risk equations (version 1) to men and women in the validation 
dataset and evaluated R2 values22, Brier scores and measures of discrimination and calibration23 24 with 
corresponding 95% confidence intervals (CIs) over the two time periods. R2 values refer to the 
proportion of variation in survival time explained by the model.  Brier scores measure predictive 
accuracy where lower values indicate better accuracy25.  The D statistic is a discrimination measure 
which quantifies the separation in survival between patients with different levels of predicted risks and 
the Harrell’s C-statistics is a discrimination metric which quantifies the extent to which people with 
higher risk scores have earlier events. Model calibration was assessed in the two time periods by 
comparing mean predicted risks with observed risks by twentieths of predicted risk. Observed risks 
were derived in each of the 20 groups using non-parametric estimates of the cumulative incidences.    
The performance metrics were calculated in the whole cohort and in the following pre-specified 
subgroups: 5-year age-sex bands, nine ethnic groups, and within each quintile of the Townsend Index, 
a measure of deprivation. We also estimated the performance metrics on a sample restricted to patients 
registered with practices using the TPP system, and therefore not used at all to derive the algorithm.  
 
Ethics  
The ethics approval for the development and validation of QCovid was granted by the  East 
Midlands-Derby Research Ethics Committee [reference 18/EM/0400]. 
 
Role of the funding source 
This study is funded by a grant from the National Institute for Health Research following a 
commission by the Chief Medical Officer for England whose office contributed to the development of 
the study question and facilitated access to relevant national datasets, contributed to interpretation of 
data, drafting of the report.      
 
RESULTS   
   
Overall study population  
Overall, 34,897,648 people in England aged 19-100 years met our inclusion criteria. Out of the 
40,136,597 people aged 19-100 who were enumerated at the 2011 Census and were alive on 24th January 
2020, 5,238,949 (13.1%) people were excluded because they did not have a valid NHS number or had 
an NHS number that could not be linked to the GPES data. This could be because they migrated out of 
England, and therefore were no longer registered with the NHS in England. Our data cover 80.0% of 
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the population in England aged 19 or over (See Supplementary Table 1). The coverage is lowest in 
London (68.2%) and highest in Yorkshire & Humber (83.7%). 
 
  
Baseline characteristics  
Table 1 shows the baseline characteristics of patients. Of these patients, 16,599,875 (47.57%) 
were men and 6,052,563 (17.34%) were of ethnic minority background. The mean age was 51.1 years, 
which is slightly higher than in the cohort used to derive the QCovid models (48.2 years).   For most 
pre-existing conditions, the estimated prevalence in the ONS Public Health Linked Data Asset is similar 
to the prevalence in the QResearch derivation cohort. However, the ONS dataset had higher proportions 
of people taking anti-leukotriene or long acting beta2-agonists, or being prescribed oral steroids in the 
last six months because of data limitations.  
26,985 (0.08%) patients had a COVID-19 related death during the first period: 24 January 2020 
to 30 April 2020). 13,177 (0.04%) patients had a COVID-19 related death during the second period (1 
May 2020 to 28 July 2020). Out of the 49,461 deaths that occurred in England over the period, 81.2% 
of these are included in our data (See Supplementary Table 1). The coverage is lowest in London 
(74.2%) and highest in the North West (84.6%). In both periods, COVID-19 deaths occurred across all 
regions, with the greatest numbers in London in period 1, (5,403 - 20.02% of all deaths) and in the 
North West in period 2 (2,411 - 18.30%). Of those who died in period 1, 15,334 (56.82%) were male; 
4523 (16.76%) were from ethnic minority groups; 22,538 (83.52%) were aged 70 and over; 8,700 
(32.24%) had diabetes; 8,293 (30.73%) had dementia; 6,990 (25.90%) were identified as living in a 
care home. Those who had a COVID-19 related death in period 2 had a similar profile to those in period 
1 but were on average older (88.4% aged 70 and over) and more likely to live in a care home (31.4%). 
   
   
Discrimination   
   
Table 2 shows the performance of the risk equations in the validation cohort for women and 
men in the two time periods. Overall, the values for the R2, D and C statistics were high and similar in 
women and men in both periods. In the first period for women, the equation explained 76.3% of the 
variation in time to COVID-19 death; Harrell’s C statistic was 0.945 and the D statistic 3.67. The 
corresponding values in men were 77.1%, 0.935 and 3.76 respectively.   All these discrimination 
metrics are higher than in the original QResearch cohort used to validate the algorithm. The results were 
similar for the second validation period. In period 2 for women, the R2 was 75.4%, Harrell’s C statistic 
0.956, the D statistic 3.58. The corresponding values for men were 77.4%, 0.944 and 3.78 
respectively.   Similar results were obtained when restricting the sample to 14,104,452 patients 
registered with practices using the TPP system (Supplementary Table 2). 
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Figure 1 displays Harrell’s C statistic by age-band for men and women in period 1 (Panel A) 
and period 2 (Panel B). The Harrell’s C statistics are over 0.7 for all age bands indicating that even 
within each age band the model discriminates well. The C statistics are lower for patients aged 90 or 
over than for younger patients.  The C statistics, R2, and D by age-band, deprivation quintile and ethnic 
group in men and women for both periods are reported in Supplementary Tables 3, 4 and 5. Performance 
was generally similar to the overall results except for age where the performance was lower within 
individual age-bands. 
   
Calibration    
Figure 2 displays the calibration plots for the COVID-19 mortality equation for men and women 
and in both periods. Overall, both sets of equations were well calibrated, as the predicted and observed 
risks were similar. However, as in the original QResearch validation cohort, the model underestimates 
the risk of COVID-19 death for those in the top 5% of the predicted risk score. 
   
Risk stratification   
  
Figure 3 shows the sensitivity values for the mortality equation in period 1 (24 January 2020 – 
30 April 2020) and period 2 (1 May 2020 – 28 July 2020) evaluated at different thresholds based on the 
centiles of the predicted absolute risk in the validation cohort. Full results are reported in Supplementary 
Table 6. The sensitivity was higher in women than in men, and in period 2 than period 1. In period 1, 
65.94% of deaths in men occurred in those in the top 5% for predicted absolute risk of death from 
Covid-19 (90 day predicted absolute risks above 0.289%) and 71.67% of deaths in women occurred in 
the top 5% (predicted absolute risks above 0.188%). In period 2, 71.10% of deaths occurred in men in 
the top 5% for predicted absolute risk of death from Covid-19 (predicted absolute risks above 0.278%) 
and 77.16% of deaths occurred in women in the top 5% (predicted absolute risks above 0.181%). 
Supplementary Figure 1 shows the sensitivity for the two time periods based on relative risks (defined 
as the ratio of the individual’s predicted absolute risk to the predicted absolute risk for a person of the 
same age and sex with a white ethnicity, body mass index of 25, and mean deprivation score with no 
other risk factors).  In period 1, 40.56% of deaths occurred in men in the top 5% for predicted relative 
risk of death from Covid-19, and 42.63% for women. In period 2, 42.62% of deaths occurred in men in 
the top 5% for predicted relative risk of death from Covid-19, and 43.57% for women. 
 
DISCUSSION   
We have validated the QCovid clinical risk prediction model for mortality due to COVID-19 
using a national external linked dataset. We have used national linked datasets from the 2011 Census, 
general practice, death registry data for a population-representative sample of nearly 35 million adults. 
The risk models have excellent discrimination (Harrell’s C statistics>0.9), are well calibrated and have 
a high sensitivity. 
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Our study had a number of important strengths. First, we used a unique linked dataset based on 
the 2011 Census for nearly 35 million people living in England. Second, we used a wide range of 
metrics, over two time periods to validate the QCovid predictive model, extending the period of 
observation beyond the original study. All the metrics in the two time periods for both men and women 
indicate that the algorithm performs well, and the metrics are comparable with the original validation 
of QCovid in the QResearch database15. Finally, we showed that the model’s performance was similar 
when restricting the sample to patients that were registered with practices using a different clinical 
computer system provider (TPP), and therefore not used to derive the QCovid model. 
 
This study also has several limitations. First, because of data limitations, we could not derive 
all predictors in the same way as in the derivation cohort. Despite these inconsistencies, the model had 
excellent discrimination and calibration. Second, we only focused on COVID-19 related deaths, but not 
hospital admissions, because of the lack of data. Finally, because the Public Health Data Asset is based 
on the 2011 Census, our sample was restricted to patients who were enumerated in 2011, that is about 
94% of the population living in England in 2011. Recent migrants were excluded from this study, but 
they tend to be younger than the native population and therefore at lower risk of COVID-19 death.
  
QCovid represents a new approach for population risk-stratification for adverse outcomes from 
COVID-19, and our validation indicates that the risk algorithm performs well on external data not used 
for its derivation. Whilst it has been specifically designed to inform UK health policy and interventions 
to manage COVID-19 related risks, it also has international potential, subject to local validation. It 
could also be deployed in a number of health and care applications, either during the current phase of 
the pandemic, or in subsequent ‘waves’ of infection. These could include supporting 
targeted recruitment for clinical trials, vaccine prioritisation, and discussions between patients and 
clinicians in relation to work and health risks, for example through weight reduction since obesity is the 
single most important modifiable risk factor for serious COVID-19 complications8.  
 
In conclusion, this study presents a robust validation of a new prediction model that could be 
used to support population risk stratification in relation to public health interventions, for example 
vaccine utilisation. We anticipate that the algorithms will be updated regularly as understanding of 
COVID-19 increases, as more data become available, as new variants emerge, effective treatments for 
COVID become available, the vaccination program rolls-out, immunity levels change or as behaviour 
in the population changes and hence we anticipate that this validation will need to be repeated on a 
regular basis.  It is important for patients/carers, and clinicians that there is a common appropriately 
developed evidence-based model that is consistently implemented and is supported by the academic, 
clinical and patient communities. This will then help ensure consistent policy and clear national 
communication between policy makers, professionals, employers and the public.     
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Box 1: Predictor variables used to validate the QCOVID model 
• Age in years (continuous) 
• Townsend deprivation score (continuous) 
• Accommodation (Neither homeless nor care home, Care home or nursing home) 
• Ethnicity in nine categories (Bangladeshi, Black African, Black Caribbean, Chinese, Indian, 
Mixed, Pakistani, White British, White other, Other) 
• Body Mass Index (kg/m2)   
• Chronic kidney disease (CKD) - (no CKD, CKD3, CKD4, CKD5) 
• Learning disability (No learning disability, Down’s Syndrome, other learning disability ) 
• Chemotherapy in last 12 months (Chemotherapy group A, B, C)   
• Respiratory cancer   
• Radiotherapy in last 6 months   
• Solid organ transplant   
• Prescribed immunosuppressant medication by GP   
• Prescribed leukotriene or long-acting beta blockers 
• Prescribed regular prednisolone   
• Sickle cell disease   
• Diabetes 
• Chronic obstructive pulmonary disease (COPD) 
• Asthma   
• Rare pulmonary diseases   
• Pulmonary hypertension or pulmonary fibrosis   
• Coronary heart disease   
• Stroke   
• Atrial Fibrillation   
• Congestive cardiac failure   
• Venous thromboembolism   
• Peripheral vascular disease   
• Congenital heart disease   
• Dementia   
• Parkinson's disease   
• Epilepsy   
• Rare neurological conditions   
• Cerebral palsy   
• Severe mental illness (bipolar disorder, schizophrenia, severe depression) 
• Osteoporotic fracture   
• Rheumatoid arthritis or Systemic lupus erythematosus   
• Cirrhosis of the liver  
Note: For the validation of the QCovid risk model, all patients with diabetes were assigned the 
coefficient type 2 diabetes. Patients with Stage 5 chronic kidney disease (CKD) were assigned the 
coefficient for CKD without transplant nor dialysis.  
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Table 1: Demographic and medical characteristics for the validation cohort and those who died 
with COVID-19 in the two time periods. Results are numbers (column %) except where 
otherwise specified. 




31.07.2020   
Total    34,897,648    26,985  13,177    
Females 18,297,773 (52.43) 11,651 (43.18) 6560 (49.78) 
Males   16,599,875 (47.57) 15,334 (56.82) 6,617 (50.22) 
mean age (SD)   51.09 (18.76) 79.98 (11.63) 82.13 (10.79) 
Age-band         
19-29 years   5,601,475 (16.05)     44 (0.16) 13 (0.10) 
30-39 years   5,268,030 (15.10)    116 (0.43)    30 (0.23) 
40-49 years   5,625,225 (16.12)    364 (1.35)   125 (0.95) 
50-59 years   6,435,204 (18.44)  1,196 (4.43)   400 (3.04) 
60-69 years   5,185,917 (14.86)  2,727 (10.11)   962 (7.30) 
70-79 years   4,225,729 (12.11)  6,280 (23.27) 2,695 (20.45) 
80-89 years 2,093,545 (6.00) 10,841 (40.17) 5,580 (42.35) 
90+ years     462,523 (1.33)  5,417 (20.07) 3,372 (25.59) 
         
Geographical region         
East Midlands   3,137,521 (8.99) 1,979 (7.33) 1,372 (10.41) 
East of England   3,987,067 (11.43) 2,549 (9.45) 1,456 (11.05) 
London   4,662,731 (13.36) 5,403 (20.02)   956 (7.26) 
North East   1,755,316 (5.03) 1,429 (5.30)   931 (7.07) 
North West   4,643,947 (13.31) 4,289 (15.89) 2,411 (18.30) 
South East   5,818,470 (16.67) 4,005 (14.84) 2,118 (16.07) 
South West   3,674,549 (10.53) 1,657 (6.14)   745 (5.65) 
West Midlands   3,643,447 (10.44) 3,284 (12.17) 1,497 (11.36) 
Yorkshire & Humber   3,574,600 (10.24) 2,390 (8.86) 1,691 (12.83) 
         
Ethnicity           
Bangladeshi     258,053 (0.74)     179 (0.66)      29 (0.22)   
Black African     520,547 (1.49)     398 (1.47)      62 (0.47)   
Black Caribbean     374,982 (1.07)     732 (2.71)     124 (0.94)   
Chinese     185,966 (0.53)     107 (0.40)      27 (0.20)   
Indian     931,247 (2.67)     800 (2.96)     216 (1.64)   
Mixed     551,567 (1.58)     184 (0.68)      67 (0.51)   
Other     835,506 (2.39)     590 (2.19)     130 (0.99)   
Pakistani     679,062 (1.95)     426 (1.58)     123 (0.93)   
White British  28,845,085 (82.66)  22,462 (83.24)  12,018 (91.20)   
White other   1,715,633 (4.92)   1,107 (4.10)     381 (2.89)   
         
Townsend deprivation q
uintile   
         
1 (most affluent)   7,491,652 (21.47)  4,993 (18.50)   2,842 (21.57)    
2   7,738,292 (22.17)  5,326 (19.74)   2,967 (22.52)   
3   6,834,804 (19.58)  5,111 (18.94)   2,647 (20.09)    
4   6,467,204 (18.53)  5,365 (19.88)  2,472 (18.76)    
5 (most deprived)   6,366,096 (18.24)  6,190 (22.94)  2,249 (17.07)    
         
Accommodation         
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
perpetuity. 
 is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint 
The copyright holder for thisthis version posted January 25, 2021. ; https://doi.org/10.1101/2021.01.22.21249968doi: medRxiv preprint 
   
 
   
 
Neither homeless or care 
home   
34,667,007 (99.34) 19,995 (74.10) 9,039 (68.60) 
Care home or 
nursing home   
   230,641 (0.66)  6,990 (25.90) 4,138 (31.40) 
        
Body mass index (kg/m2)         
BMI < 18.5      393,928 (1.13)   983 (3.64)   614 (4.66) 
BMI 18.5-24.99    6,658,276 (19.08) 5,776 (21.40) 2,965 (22.50) 
BMI 25-29.99    6,661,721 (19.09) 5,552 (20.57) 2,385 (18.10) 
BMI 30+    5,661,007 (16.22) 5,540 (20.53) 2,066 (15.68) 
BMI not recorded   15,522,716 (44.48) 9,134 (33.85) 5,147 (39.06) 
         
Chronic kidney disease 
(CKD)  
      
no CKD   34,392,544 (98.55) 24,425 (90.51) 11,939 (90.60) 
CKD3      436,595 (1.25)  1,820 (6.74)    914 (6.94) 
CKD4       45,638 (0.13)    452 (1.68)    205 (1.56) 
CKD5       22,871 (0.07)    288 (1.07)    119 (0.90) 
        
Learning disability:       
No learning disability   34,393,288 (98.55) 25,300 (93.76) 12,386 (94.00) 
Learning disability      490,357 (1.41)  1,616 (5.99) * 
Down’s Syndrome       14,003 (0.04)     69 (0.26) * 
        
Chemotherapy:       
No chemotherapy in last 
12 months   
34,776,317 (99.65) 26,472 (98.10) 12,908 (97.96) 
Chemotherapy group A       38,956 (0.11)    128 (0.47)     62 (0.47) 
Chemotherapy group B       76,763 (0.22)    339 (1.26)    180 (1.37) 
Chemotherapy group C        5,612 (0.02)     46 (0.17)     27 (0.20) 
         
Cancer and 
immunosuppression: 
      
Blood cancer      336,990 (0.97)    897 (3.32)    465 (3.53) 
Respiratory cancer        9,720 (0.03)    142 (0.53)     66 (0.50) 
Radiotherapy in last 6 
months   
    56,252 (0.16)    174 (0.64)    100 (0.76) 
Solid organ transplant        3,488 (0.01)     26 (0.10) * 
Prescribed 
immunosuppressant 
medication by GP   
     7,237 (0.02)     20 (0.07) * 
Prescribed leukotriene or 
LABA   
 2,362,855 (6.77)  4,956 (18.37)  2,319 (17.60) 
prescribed regular 
prednisolone   
   404,467 (1.16)  2,124 (7.87)  1,028 (7.80) 
         
Other co-morbidities         
Diabetes  3,087,792 (8.85)  8,700 (32.24) 3,650 (27.70) 
COPD    1,053,783 (3.02)  3,814 (14.13)  1,809 (13.73) 
asthma    4,382,954 (12.56)  3,344 (12.39)  1,504 (11.41) 
Rare pulmonary diseases      373,807 (1.07)  1,707 (6.33)    734 (5.57) 
Pulmonary hypertension 
or pulmonary fibrosis   
   127,760 (0.37)  1,158 (4.29)    502 (3.81) 
Coronary heart disease    1,549,243 (4.44)  5,946 (22.03)  2,861 (21.71) 
Stroke      902,277 (2.59)  5,086 (18.85)  2,685 (20.38) 
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Atrial Fibrillation    1,096,209 (3.14)  5,237 (19.41)  2,894 (21.96) 
Congestive cardiac failure      545,617 (1.56)  3,739 (13.86)  1,830 (13.89) 
Venous 
thromboembolism   
     8,878 (0.03)     35 (0.13) * 
Peripheral vascular 
disease   
   303,118 (0.87)  1,588 (5.88)    771 (5.85) 
Congenital heart disease          359 (0.00) * 0 (0.00) 
Dementia      414,540 (1.19)  8,293 (30.73) 4,699 (35.66) 
Parkinson's disease      113,647 (0.33)  1,021 (3.78)    573 (4.35) 
Epilepsy      405,047 (1.16)    797 (2.95)    387 (2.94) 
Rare neurological 
conditions   
    27,583 (0.08)    149 (0.55)     48 (0.36) 
Cerebral palsy        4,350 (0.01)     31 (0.11) * 
Severe mental illness    6,574,526 (18.84)  5,341 (19.79)  2,541 (19.28) 
Osteoporotic fracture       29,153 (0.08)    194 (0.72)     92 (0.70) 
Rheumatoid arthritis or 
SLE   
   315,431 (0.90)    696 (2.58)    369 (2.80) 
Cirrhosis of the liver       81,753 (0.23)    241 (0.89)    114 (0.87) 
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Table 2 Performance of the risk models to predict risk of COVID-19 death in the validation 
cohort.   
 
 Period 1 (24/01/2020 -30/04/2020)  Period 2 (01/05/2020 -28/07/2020)  
     
    COVID -19 
death   
COVID -19 
death   
COVID -19 
death   
COVID -19 
death   
   females   males   females   males   
   Estimate (95% 
CI)  
 Estimate (95% 
CI)   
Estimate (95% 
CI)  
 Estimate (95% 
CI)   
          
R2 statistic   0.763  
(0.760 to 0.766) 
 0.771  
(0.769 to 0.774) 
 
 0.754  
(0.750 to 0.757) 
 
 
   0.774  




D statistic    3.671  
(3.640 to 3.702) 
 
 3.761  
(3.732 to 3.789) 
3.579  
(3.542 to 3.616) 
3.782  
(3.739 to 3.826) 
Harrell’s C 
statistic   
 0.945  
(0.943 to 0.947) 
 
 0.935  
(0.933 to 0.937) 
 
0.956  
(0.954 to 0.958) 
0.944  
(0.942 to 0.946) 
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A – Period 1 (24/01/2020 - 30/04/2020) 
 
B– Period 2 (01/05/2020 - 28/07/2020) 
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Figure 2: Predicted and observed risk of covid-19 related death in first study period (24 January to 30 
April 2020) 
 
Figure 3:  Sensitivity for covid-19 related death in validation cohort for period 1 (24 January 2020 – 
30 April 2020) and period 2 (1 May 2020 – 28 July 2020) 
 
 
Centiles based on predicted absolute risks in men and women in each period. Sensitivity (cumulative 
% deaths) is percentage of total deaths in the period that occurred within the group of patients above 
the predicted risk threshold. 
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Appendix 
Supplementary Table 1: Population and Covid-19 deaths in the ONS Public Health Data Asset 
compared to England (up to 28th July 2020) 
 Population COVID-19 deaths 
  In the 
Cohort 








Midlands   
3,137,521 3,779,186 83.0%           3,351   3,977  84.3% 
East of 
England   
3,987,067 4,822,148 82.7%           4,005  5,113  78.3% 
London   4,662,731 6,834,636 68.2%           6,359  8,570  74.2% 
North East   1,755,316 2,108,996 83.2%           2,360  2,834  83.3% 
North West   4,643,947 5,696,784 81.5%           6,700  7,923  84.6% 
South East   5,818,470 7,107,605 81.9%           6,123  7,374  83.0% 
South West   3,674,549 4,457,165 82.4%           2,402  2,916  82.4% 
West 
Midlands   
3,643,447 4,566,619 79.8%           4,781  5,898  81.1% 
Yorkshire & 
Humber   
3,574,600 4,271,381 83.7%           4,081  4,856  84.0% 
England 34,897,648 43,644,520 80.0%         40,162  49,461  81.2% 
Note: Population for England and deaths that occurred in England are for people 19 or over, whilst 
our cohort is limited to people aged between 19 and 100. Source: Population for England: Estimates 
of the population for the UK, England and Wales, Scotland and Northern Ireland (ONS); Deaths in 
England: Deaths registered weekly in England and Wales, provisional (ONS). 
 
 
Supplementary Table 2: Performance of the risk models to predict risk of COVID-19 death in 
14,104,452 patients registered with practices using the TPP System 
 
 Period 1 
(24/01/2020 -
30/04/2020)  




     
    COVID -19 
death   
COVID -19 
death   
COVID -19 
death   
COVID -19 
death   
   females   males   females   males   
   Estimate (95% 
CI)  
 Estimate (95% 
CI)   
Estimate (95% 
CI)  
 Estimate (95% 
CI)   
          
R2 statistic    0.778  
(0.773 to 0.783) 
0.785  
(0.780 to 0.790) 
0.769  
(0.763 to 0.775) 
0.766  
(0.760 to 0.772) 
D statistic   3.833  
(3.775 to 3.892) 
3.911  
(3.857 to 3.965) 
3.731  
(3.669 to 3.793) 
3.704  
(3.639 to 3.769) 
Harrell’s C 
statistic   
0.945  
(0.942 to 0.948) 
0.934  
(0.931 to 0.937) 
0.957  
(0.953 to 0.960) 
0.948  
(0.945 to 0.952) 
Brier score  0.0011 0.0015 0.0007 0.0008 
 
 
Supplementary Table 3: Performance of the risk models to predict risk of COVID-19 
death in the validation cohort by subgroup using Harrell’s C statistic (95% CI).  
 Period 1 (24/01/2020 -30/04/2020)  Period 2 (01/05/2020 -28/07/2020)  
      
   COVID -19 
death   
COVID -19 
death   
COVID -19 
death   
COVID -19 
death    
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   females   males   females   males    
Age band             
19-40 0.810 (0.753 to 
0.866) 
0.833 (0.784 to 
0.881) 
0.800 (0.676 to 
0.925) 
0.786 (0.685 to 
0.886) 
40-45 0.856 (0.798 to 
0.913) 
0.811 (0.758 to 
0.865) 
0.746 (0.659 to 
0.833) 
0.763 (0.667 to 
0.860) 
45-50 0.849 (0.808 to 
0.890) 
0.841 (0.809 to 
0.872) 
0.809 (0.723 to 
0.895) 
0.768 (0.692 to 
0.843) 
50-55 0.874 (0.847 to 
0.901) 
0.834 (0.808 to 
0.860) 
0.782 (0.716 to 
0.849) 
0.779 (0.731 to 
0.827) 
55-60 0.844 (0.819 to 
0.869) 
0.796 (0.774 to 
0.818) 
0.805 (0.754 to 
0.856) 
0.809 (0.776 to 
0.842) 
60-65 0.851 (0.831 to 
0.872) 
0.808 (0.791 to 
0.825) 
0.818 (0.777 to 
0.858) 
0.788 (0.758 to 
0.819) 
65-70 0.844 (0.826 to 
0.861) 
0.803 (0.789 to 
0.817) 
0.787 (0.755 to 
0.819) 
0.817 (0.794 to 
0.839) 
70-75 0.851 (0.837 to 
0.865) 
0.796 (0.785 to 
0.807) 
0.857 (0.838 to 
0.876) 
0.826 (0.810 to 
0.842) 
75-80 0.846 (0.835 to 
0.857) 
0.808 (0.798 to 
0.817) 
0.839 (0.824 to 
0.855) 
0.821 (0.807 to 
0.835) 
80-85 0.819 (0.810 to 
0.828) 
0.787 (0.779 to 
0.796) 
0.828 (0.816 to 
0.840) 
0.803 (0.791 to 
0.815) 
85-90 0.793 (0.784 to 
0.802) 
0.768 (0.759 to 
0.777) 
0.785 (0.774 to 
0.797) 
0.755 (0.742 to 
0.769) 
90+ 0.736 (0.727 to 
0.744) 
0.729 (0.719 to 
0.740) 
0.750 (0.740 to 
0.760) 
0.720 (0.705 to 
0.735) 
           
Ethnicity            
Bangladeshi 0.942 (0.918 to 
0.966) 
0.939 (0.921 to 
0.957) 
0.932 (0.891 to 
0.973) 
0.918 (0.863 to 
0.974) 
Black African 0.888 (0.859 to 
0.917) 
0.906 (0.888 to 
0.925) 
0.839 (0.743 to 
0.935) 
0.908 (0.870 to 
0.946) 
Black Caribbean 0.924 (0.912 to 
0.937) 
0.930 (0.920 to 
0.939) 
0.939 (0.914 to 
0.965) 
0.921 (0.890 to 
0.951) 
Chinese 0.960 (0.937 to 
0.984) 
0.914 (0.877 to 
0.950) 
0.927 (0.861 to 
0.993) 
0.955 (0.913 to 
0.997) 
Indian 0.939 (0.929 to 
0.949) 
0.916 (0.906 to 
0.926) 
0.929 (0.907 to 
0.950) 
0.901 (0.878 to 
0.924) 
Mixed 0.947 (0.923 to 
0.972) 
0.972 (0.961 to 
0.984) 
0.980 (0.966 to 
0.994) 
0.963 (0.946 to 
0.979) 
Other 0.935 (0.919 to 
0.950) 
0.905 (0.892 to 
0.918) 
0.883 (0.826 to 
0.939) 
0.905 (0.880 to 
0.930) 
Pakistani 0.918 (0.899 to 
0.937) 
0.923 (0.908 to 
0.937) 
0.948 (0.926 to 
0.971) 
0.897 (0.865 to 
0.930) 
White British 0.946 (0.944 to 
0.948) 
0.935 (0.933 to 
0.937) 
0.956 (0.954 to 
0.958) 
0.947 (0.944 to 
0.949) 
White other 0.963 (0.956 to 
0.969) 
0.950 (0.943 to 
0.957) 
0.968 (0.956 to 
0.981) 
0.951 (0.939 to 
0.963) 
          
Townsend 
quintile   
        
1 (most affluent)   0.945 (0.940 to 
0.949) 
0.933 (0.929 to 
0.937) 
0.961 (0.957 to 
0.965) 
0.949 (0.944 to 
0.954) 
2   0.945 (0.940 to 
0.949) 
0.935 (0.932 to 
0.939) 
0.955 (0.951 to 
0.960) 
0.947 (0.942 to 
0.952) 
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3   0.947 (0.943 to 
0.951) 
0.933 (0.929 to 
0.937) 
0.958 (0.954 to 
0.963) 
0.945 (0.940 to 
0.950) 
4   0.946 (0.942 to 
0.949) 
0.938 (0.935 to 
0.942) 
0.956 (0.952 to 
0.960) 
0.944 (0.939 to 
0.950) 
5 (most 
deprived)   
0.943 (0.939 to 
0.947) 
0.934 (0.930 to 
0.937) 
0.952 (0.946 to 
0.957) 
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Supplementary Table 4: D statistic of the risk models to predict risk of COVID-19 
death the validation cohort by subgroup    
  Period 1 (24/01/2020 -30/04/2020)  Period 2 (01/05/2020 -28/07/2020)  
      
   COVID -19 
death   
COVID -19 
death   
COVID -19 
death   
COVID -19 
death   
   females   males   females   males   
Age band             
19-40 2.175 (1.808 to 
2.541) 
2.551 (2.192 to 
2.910) 
2.376 (1.631 to 
3.121) 
1.857 (1.230 to 
2.484) 
40-45 2.537 (2.052 to 
3.022) 
2.212 (1.826 to 
2.598) 
1.360 (0.641 to 
2.078) 
1.573 (0.942 to 
2.204) 
45-50 2.660 (2.320 to 
3.001) 
2.331 (2.053 to 
2.610) 
1.966 (1.426 to 
2.505) 
1.865 (1.401 to 
2.329) 
50-55 2.627 (2.378 to 
2.876) 
2.355 (2.144 to 
2.566) 
1.961 (1.522 to 
2.400) 
1.780 (1.462 to 
2.099) 
55-60 2.434 (2.226 to 
2.641) 
2.099 (1.943 to 
2.255) 
1.946 (1.607 to 
2.285) 
2.028 (1.773 to 
2.283) 
60-65 2.603 (2.427 to 
2.779) 
2.260 (2.129 to 
2.390) 
2.003 (1.734 to 
2.271) 
1.923 (1.713 to 
2.133) 
65-70 2.433 (2.284 to 
2.583) 
2.299 (2.185 to 
2.414) 
1.904 (1.694 to 
2.115) 
2.094 (1.918 to 
2.269) 
70-75 2.735 (2.610 to 
2.860) 
2.273 (2.182 to 
2.365) 
2.668 (2.497 to 
2.839) 
2.405 (2.268 to 
2.541) 
75-80 2.609 (2.513 to 
2.705) 
2.241 (2.168 to 
2.314) 
2.454 (2.318 to 
2.590) 
2.297 (2.187 to 
2.408) 
80-85 2.304 (2.229 to 
2.378) 
2.135 (2.071 to 
2.199) 
2.285 (2.188 to 
2.382) 
2.218 (2.123 to 
2.312) 
85-90 2.011 (1.945 to 
2.077) 
1.800 (1.739 to 
1.861) 
1.945 (1.861 to 
2.030) 
1.739 (1.652 to 
1.826) 
90+ 1.444 (1.385 to 
1.503) 
1.446 (1.381 to 
1.511) 
1.327 (1.263 to 
1.392) 
1.347 (1.254 to 
1.440) 
           
Ethnicity            
Bangladeshi 3.370 (2.920 to 
3.820) 
4.803 (4.345 to 
5.261) 
3.666 (2.323 to 
5.010) 
2.828 (2.073 to 
3.582) 
Black African 3.560 (3.199 to 
3.920) 
3.435 (3.196 to 
3.675) 
2.648 (1.845 to 
3.451) 
2.739 (2.247 to 
3.232) 
Black Caribbean 3.973 (3.692 to 
4.254) 
3.426 (3.259 to 
3.594) 
3.670 (3.075 to 
4.266) 
3.314 (2.922 to 
3.705) 
Chinese 4.408 (3.753 to 
5.063) 
4.730 (4.068 to 
5.393) 
6.309 (4.459 to 
8.160) 
4.571 (3.063 to 
6.079) 
Indian 3.504 (3.304 to 
3.704) 
3.338 (3.186 to 
3.490) 
3.705 (3.289 to 
4.121) 
2.826 (2.504 to 
3.148) 
Mixed 4.039 (3.612 to 
4.466) 
4.171 (3.818 to 
4.525) 
5.267 (4.447 to 
6.086) 
3.900 (3.336 to 
4.464) 
Other 3.994 (3.701 to 
4.286) 
3.725 (3.502 to 
3.948) 
3.317 (2.786 to 
3.848) 
3.070 (2.640 to 
3.500) 
Pakistani 3.567 (3.240 to 
3.895) 
3.381 (3.148 to 
3.615) 
3.362 (2.832 to 
3.892) 
2.623 (2.267 to 
2.979) 
White British 3.487 (3.456 to 
3.517) 
3.761 (3.729 to 
3.792) 
3.595 (3.556 to 
3.633) 
3.993 (3.945 to 
4.041) 
White other 3.749 (3.614 to 
3.884) 
4.007 (3.857 to 
4.158) 
3.902 (3.667 to 
4.137) 
4.223 (3.929 to 
4.517) 
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Townsend 
quintile   
        
1 (most affluent)   3.667 (3.591 to 
3.744) 
3.738 (3.674 to 
3.803) 
3.954 (3.863 to 
4.045) 
4.253 (4.153 to 
4.353) 
2   3.905 (3.826 to 
3.985) 
3.875 (3.809 to 
3.940) 
3.640 (3.558 to 
3.722) 
3.686 (3.605 to 
3.766) 
3   3.764 (3.690 to 
3.838) 
4.006 (3.931 to 
4.082) 
3.819 (3.727 to 
3.911) 
3.562 (3.476 to 
3.647) 
4   3.364 (3.304 to 
3.424) 
4.070 (3.997 to 
4.143) 
3.803 (3.706 to 
3.899) 
3.664 (3.570 to 
3.758) 
5 (most 
deprived)   
3.274 (3.218 to 
3.330) 
3.920 (3.854 to 
3.985) 
3.601 (3.509 to 
3.693) 
3.696 (3.585 to 
3.807) 
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Supplementary Table 5: R-squared of the risk models to predict risk of COVID-19 
death the validation cohort by subgroup 
 Period 1 (24/01/2020 -30/04/2020)  Period 2 (01/05/2020 -28/07/2020)  
      
   COVID -19 
death   
COVID -19 
death   
COVID -19 
death   
COVID -19 
death   
   females   males   females   males   
Age band             
19-40 0.530 (0.438 to 
0.607) 
0.608 (0.534 to 
0.669) 
0.574 (0.388 to 
0.699) 
0.451 (0.265 to 
0.596) 
40-45 0.606 (0.501 to 
0.686) 
0.539 (0.443 to 
0.617) 
0.306 (0.089 to 
0.508) 
0.371 (0.175 to 
0.537) 
45-50 0.628 (0.562 to 
0.683) 
0.565 (0.502 to 
0.619) 
0.480 (0.327 to 
0.600) 
0.454 (0.319 to 
0.564) 
50-55 0.622 (0.574 to 
0.664) 
0.570 (0.523 to 
0.611) 
0.479 (0.356 to 
0.579) 
0.431 (0.338 to 
0.513) 
55-60 0.586 (0.542 to 
0.625) 
0.513 (0.474 to 
0.548) 
0.475 (0.382 to 
0.555) 
0.495 (0.429 to 
0.554) 
60-65 0.618 (0.584 to 
0.648) 
0.549 (0.520 to 
0.577) 
0.489 (0.418 to 
0.552) 
0.469 (0.412 to 
0.521) 
65-70 0.586 (0.555 to 
0.614) 
0.558 (0.533 to 
0.582) 
0.464 (0.407 to 
0.516) 
0.511 (0.468 to 
0.551) 
70-75 0.641 (0.619 to 
0.661) 
0.552 (0.532 to 
0.572) 
0.630 (0.598 to 
0.658) 
0.580 (0.551 to 
0.607) 
75-80 0.619 (0.601 to 
0.636) 
0.545 (0.529 to 
0.561) 
0.590 (0.562 to 
0.616) 
0.558 (0.533 to 
0.581) 
80-85 0.559 (0.543 to 
0.574) 
0.521 (0.506 to 
0.536) 
0.555 (0.533 to 
0.575) 
0.540 (0.518 to 
0.561) 
85-90 0.491 (0.475 to 
0.507) 
0.436 (0.419 to 
0.452) 
0.475 (0.453 to 
0.496) 
0.419 (0.394 to 
0.443) 
90+ 0.332 (0.314 to 
0.350) 
0.333 (0.313 to 
0.353) 
0.296 (0.276 to 
0.316) 
0.302 (0.273 to 
0.331) 
           
Ethnicity            
Bangladeshi 0.731 (0.671 to 
0.777) 
0.846 (0.818 to 
0.869) 
0.762 (0.563 to 
0.857) 
0.656 (0.506 to 
0.754) 
Black African 0.752 (0.710 to 
0.786) 
0.738 (0.709 to 
0.763) 
0.626 (0.448 to 
0.740) 
0.642 (0.547 to 
0.714) 
Black Caribbean 0.790 (0.765 to 
0.812) 
0.737 (0.717 to 
0.755) 
0.763 (0.693 to 
0.813) 
0.724 (0.671 to 
0.766) 
Chinese 0.823 (0.771 to 
0.860) 
0.842 (0.798 to 
0.874) 
0.905 (0.826 to 
0.941) 
0.833 (0.691 to 
0.898) 
Indian 0.746 (0.723 to 
0.766) 
0.727 (0.708 to 
0.744) 
0.766 (0.721 to 
0.802) 
0.656 (0.600 to 
0.703) 
Mixed 0.796 (0.757 to 
0.826) 
0.806 (0.777 to 
0.830) 
0.869 (0.825 to 
0.898) 
0.784 (0.727 to 
0.826) 
Other 0.792 (0.766 to 
0.814) 
0.768 (0.745 to 
0.788) 
0.724 (0.649 to 
0.780) 
0.692 (0.625 to 
0.745) 
Pakistani 0.752 (0.715 to 
0.784) 
0.732 (0.703 to 
0.757) 
0.730 (0.657 to 
0.783) 
0.622 (0.551 to 
0.679) 
White British 0.744 (0.740 to 
0.747) 
0.771 (0.768 to 
0.774) 
0.755 (0.751 to 
0.759) 
0.792 (0.788 to 
0.796) 
White other 0.770 (0.757 to 
0.783) 
0.793 (0.780 to 
0.805) 
0.784 (0.762 to 
0.803) 
0.810 (0.787 to 
0.830) 
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Townsend 
quintile   
        
1 (most affluent)   0.763 (0.755 to 
0.770) 
0.769 (0.763 to 
0.775) 
0.789 (0.781 to 
0.796) 
0.812 (0.805 to 
0.819) 
2   0.785 (0.777 to 
0.791) 
0.782 (0.776 to 
0.787) 
0.760 (0.751 to 
0.768) 
0.764 (0.756 to 
0.772) 
3   0.772 (0.765 to 
0.779) 
0.793 (0.787 to 
0.799) 
0.777 (0.768 to 
0.785) 
0.752 (0.743 to 
0.760) 
4   0.730 (0.723 to 
0.737) 
0.798 (0.792 to 
0.804) 
0.775 (0.766 to 
0.784) 
0.762 (0.753 to 
0.771) 
5 (most 
deprived)   
0.719 (0.712 to 
0.726) 
0.786 (0.780 to 
0.791) 
0.756 (0.746 to 
0.765) 
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Supplementary Table 6 Sensitivity for covid-19 related death by sex at different absolute risk 
thresholds 









deaths based on 
absolute risk 
(sensitivity†) 
Men, Period 1 (24 January 2020 to 30 April 2020)  
1 165998 0.9195 5169 33.71 
2 165999 0.5593 1968 46.54 
3 165999 0.4197 1327 55.20 
4 165999 0.3414 926 61.24 
5 165998 0.2890 721 65.94 
6 165999 0.2506 578 69.71 
7 165999 0.2207 472 72.79 
8 165999 0.1965 390 75.33 
9 165998 0.1763 359 77.67 
10 165999 0.1593 306 79.67 
11 165999 0.1447 239 81.22 
12 165999 0.1319 258 82.91 
13 165998 0.1206 207 84.26 
14 165999 0.1107 191 85.50 
15 165999 0.1019 172 86.62 
16 165999 0.0939 163 87.69 
17 165998 0.0868 128 88.52 
18 165999 0.0804 135 89.40 
19 165999 0.0746 115 90.15 
20 165999 0.0693 106 90.84 
21 165998 0.0645 97 91.48 
22 165999 0.0600 79 91.99 
23 165999 0.0559 86 92.55 
24 165999 0.0520 59 92.94 
25 165998 0.0483 71 93.40 
 
Women, Period 1 (24 January 2020 to 30 April 2020)  
1 182977 0.7353 4227 36.28 
2 182978 0.4011 1752 51.32 
3 182978 0.2862 1049 60.32 
4 182977 0.2263 728 66.57 
5 182978 0.1884 594 71.67 
6 182978 0.1611 443 75.47 
7 182978 0.1401 331 78.31 
8 182977 0.1231 273 80.65 
9 182978 0.1090 232 82.65 
10 182978 0.0971 219 84.52 
11 182978 0.0869 151 85.82 
12 182977 0.0781 127 86.91 
13 182978 0.0705 140 88.11 
14 182978 0.0637 120 89.14 
15 182977 0.0577 108 90.07 
16 182978 0.0525 77 90.73 
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17 182978 0.0478 81 91.43 
18 182978 0.0437 69 92.02 
19 182977 0.0401 63 92.56 
20 182978 0.0369 60 93.07 
21 182978 0.0340 60 93.59 
22 182978 0.0313 53 94.04 
23 182977 0.0289 38 94.37 
24 182978 0.0267 46 94.76 
25 182978 0.0247 32 95.04 
 
Men, Period 2 (1 May 2020 to 28 July 2020)  
1 165275 0.8429 2531 38.25 
2 165275 0.5263 891 51.72 
3 165275 0.3997 551 60.04 
4 165275 0.3272 423 66.43 
5 165275 0.2781 309 71.10 
6 165275 0.2419 267 75.14 
7 165275 0.2135 207 78.27 
8 165275 0.1904 160 80.69 
9 165275 0.1712 117 82.45 
10 165275 0.1548 103 84.01 
11 165275 0.1407 89 85.36 
12 165275 0.1284 79 86.55 
13 165275 0.1175 88 87.88 
14 165275 0.1079 73 88.98 
15 165276 0.0994 49 89.72 
16 165275 0.0917 35 90.25 
17 165275 0.0848 50 91.01 
18 165275 0.0786 38 91.58 
19 165275 0.0730 51 92.35 
20 165275 0.0678 25 92.73 
21 165275 0.0631 24 93.09 
22 165275 0.0587 37 93.65 
23 165275 0.0547 25 94.03 
24 165275 0.0509 32 94.51 
25 165275 0.0473 21 94.83 
 
Women, Period 2 (1 May 2020 to 28 July 2020)  
1 182260 0.6629 2793 42.58 
2 182261 0.3734 994 57.73 
3 182260 0.2710 591 66.74 
4 182261 0.2162 367 72.33 
5 182261 0.1809 317 77.16 
6 182260 0.1552 229 80.66 
7 182261 0.1353 152 82.97 
8 182261 0.1190 147 85.21 
9 182260 0.1055 122 87.07 
10 182261 0.0941 83 88.34 
11 182261 0.0843 71 89.42 
12 182260 0.0758 74 90.55 
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13 182261 0.0684 56 91.40 
14 182261 0.0619 58 92.29 
15 182260 0.0562 31 92.76 
16 182261 0.0511 40 93.37 
17 182261 0.0466 36 93.92 
18 182260 0.0427 36 94.47 
19 182261 0.0392 21 94.79 
20 182261 0.0360 21 95.11 
21 182260 0.0332 23 95.46 
22 182261 0.0306 22 95.79 
23 182260 0.0283 19 96.08 
24 182261 0.0262 13 96.28 
25 182261 0.0242 18 96.55 
Risk threshold is the centile value giving the cut-off of predicted risk over 97 days for defining each group 
Sensitivity is percentage of total deaths over 97 days that occurred within the group of patients above the predicted risk 
threshold 
 
Supplementary Figure 1 
 
Centiles based on predicted relative risks compared with someone of the same age/sex with no risk 
factors. Sensitivity is percentage of total deaths in the period that occurred within the group of patients 
above the predicted risk threshold. 
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